Actos & Bladder Cancer

In 2012, an article was published in Urology titled “Association between pioglitazone and urothelial bladder cancer.” by Y. Barbalat et al. that aimed to “present the current literature reporting the association between pioglitazone and bladder cancer.”  To be clear, “pioglitazone” is the chemical name for the diabetes drug, Actos, manufactured by Takeda

In 2014, a team of researchers led by SM Jin published the results of a study that aimed to determined if low doses of pioglitazone (Actos) also raised the risk for bladder cancer among diabetic patients.  It has already been demonstrated by many other studies that long-term and high-dose Actos therapy dramatically raises the risk